https://www.fiercebiotech.com/biotech/incyte-sinks-as-itacitinib-fails-pivotal-test-acute-gvhd
So Incyte accepted the trial result and moved on. Unlike MSB who dredge the data from failed trials, managed to cherry pick something they could claim as a "success" and then declared they would try to do a new trial in a special group of patients where efficacy seemed it might be better. A different dose at a different time in combination with a different drug in patients of a particular age...
Ann: Trading Halt, page-220
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.52 |
Change
0.030(2.01%) |
Mkt cap ! $1.689B | |||
| Open | High | Low | Value | Volume |
| $1.57 | $1.58 | $1.41 | $12.48M | 8.349M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 28310 | $1.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.52 | 81328 | 8 |
View Market Depth
| Last trade - 13.05pm 07/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |